Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 28-12-2015
AUM:
₹ 1,295.83 Cr
Expense Ratio
2.1%
Benchmark
NIFTY Pharma TRI
ISIN
INF277K016A9
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Meeta Shetty, Rajat Srivastava
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | 3.91 | 22.29 | 17.52 |
| Nifty Pharma TRI | 4.96 | 21.68 | 15.36 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
30.6375
Last change
-0.14 (-0.4537%)
Fund Size (AUM)
₹ 1,295.83 Cr
Performance
11.93% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund Manager
Meeta Shetty, Rajat Srivastava
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.59 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.13 |
| HEALTHCARE GLOBAL ENTERPRISES LTD EQ | 4.96 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 4.9 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 4.71 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.52 |
| ALKEM LABORATORIES LIMITED EQ | 4.42 |
| ABBOTT INDIA LIMITED EQ | 4.02 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 3.92 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 3.56 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 96.3 |
| Chemicals | 2.17 |